New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
08:11 EDTGHDXGenomic Health's Oncotype DX colon cancer survey shows positive impact
Genomic Health announced results from the Oncotype DX colon cancer test studies highlighting the body of clinical evidence for the Oncotype DX colon cancer test and its real-life impact on patient and physician treatment decisions. Through an analysis of physician recommendations and patient treatment preferences before and after receiving the Oncotype DX colon cancer test results, this study demonstrated that the test increased concordance between physician and patient treatment choice from 66% to 96%, that the quantitative information provided by the Recurrence Score result influenced a majority of patients' treatment decisions and physicians' treatment recommendations, and increased physicians' confidence in their own recommendations. Patients' anxiety was also significantly reduced, which may improve adherence to their treatment plan and ultimately lead to better health outcomes.
News For GHDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
08:05 EDTGHDXGenomic Health reports publication of results from second Oncotype DX validation
Genomic Health announced multiple upcoming presentations at the 2014 Society of Urologic Oncology Annual Meeting, including the second large, independent clinical validation study of the Oncotype DX prostate cancer test and results from the first prostate cancer decision impact study. The results from the latest validation study of the test, conducted in collaboration with the Center for Prostate Disease Research, have been accepted for publication in European Urology. Separately, the results of the first decision impact study of the Oncotype DX prostate cancer test, conducted in collaboration with academic and community practices at Columbia University, Delaware Valley Urology and Orange County Urology, have been accepted for publication in Urology Practice, an official journal of the American Urological Association. Additionally, Genomic Health will present results from its first liquid biopsy study assessing multiple technologies, including next-generation sequencing, for their ability to detect and analyze the presence of bladder cancer in urine.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use